Hepatitis C genotype 4 with normal transaminases: Correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 5, 2013, Pages 479-484

  Abdel Rahman, Mahasen ^a   Saad, Yasmin ^a   El Raziky, Maissa ^a   Zayed, Naglaa ^a   El Akel, Wafaa ^a   Said, Mohamed ^a   El Beshlawy, Mohamed ^a   Esmat, Gamal ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; DISEASE SEVERITY; EGYPT; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LABORATORY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS HEPATITIS;

ADULT; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EGYPT; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MULTIVARIATE ANALYSIS; PLATELET COUNT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; SEX FACTORS; VIRAL LOAD;

EID: 84886952425     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.02.009     Document Type: Article

References (34)

1. National Institute of Health, USA NIH consensus statement on management of hepatitis C. NIH Consensus State Sci Statements 2002, 19:1-46.
2. Ghany M.G., Strader M.G., Thomas D.L., Seef L.B. Diagnosis management and treatment of hepatitis C: an update AASLD practice guidelines. Hepatology 2009, 49:1335-1374.
3. Alberti A., Noventa F., Benvgnu L., Boccato S., Gatta A. Prevalence of liver disease in a population of asymptomatic individuals with hepatitis C virus infection. Ann Intern Med 2002, 137:961-964.
4. Prati D., Shiffman M.L., Diago M., Gane E., Rajender Reedy K., Pockros P., et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol 2006, 44:679-685.
5. Prati D., Tailoi E., Zanella A., Della Tore E., Butelli S., del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
6. Zapata R. Clinical approach to the patients with chronic hepatitis C infection and normal aminotransferases. Ann Hepatol 2010, 9(1):S72-S79.
7. Puoti C., Castellacci R., Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?. Dig Liver Dis 2000, 32:634-643.
8. Persico M., Persico E., Suozzo R., Conte S., De Seta M., Coppola M., et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000, 118:760-764.
9. Zeuzem S., Alberti A., Rosenberg W., Marcellin P., Daigo M., Negro F., et al. Review Article: Management of patients with chronic hepatitis C virus infection and normal alanine aminotransferase activity. Aliment Pharmacol Ther 2006, 24:1133-1149.
10. Shiffman M.L., Diago M., Tran A., Pockros P., Reindollar R., Prati D., et al. Chronic hepatitis C in patients with persistently normal alanine aminotransferase levels. Clin Gasreoenterol Hepatol 2006, 4:645-652.
11. Martinot-Peignoux M., Boyer N., Cazals-Hatem D., Pham B.N., Gervais A., Le Breton V., et al. Prospective study on anti hepatitis C virus- positive patients with persistently normal serum alanine aminotransferase with or without detectable serum hepatitis C virus RNA. Hepatology 2001, 34:1000-1005.
12. Persioco M., Perrotta S., Persico E., Terracciano L., Folgori A., Ruggeri L., et al. Hepatitis C virus carriers with persistently normal ALT levels: Biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 2006, 13:290-296.
13. Okanoue T., Minami M., Makiyama A., Sumida Y., Yasui K., Itoh Y. Natural course of asymptomatic hepatitis C virus- infected patients and hepatocellular carcinoma after Interferon therapy. Clin Gastroenterol Hepatol 2005, 3(10 Suppl 2):S89-S91.
14. Puoti C. Hepatitis C virus with normal transaminase levels. Dig Dis 2007, 25:277-278.
15. Fried M.W. Hepatitis C infection with normal liver chemistry tests. Clin Gastroentrol Hepatol 2008, 6:503-505.
16. Abdel-Aziz F., Habib M., Mohamed M.K., Abdel-Hamid M., Gamil F., Madkour S., et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000, 32:111-115.
17. Frank C., Mohamed M.K., Strickland G.T., Lavanchy D., Arthur R.R., Magder L.S., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355:887-891.
18. Nafeh M.A., Medhat A., Shehata M., Mikhail N.N., Swifee Y., Abdel-Hamid M., et al. Hepatitis C in a community in Upper Egypt: I Cross-sectional survey. Am J Trop Med Hyg 2000, 63:236-241.
19. El-Sadawy M., Ragab H., el-Toukhy H., el-Mor Ael L., Mangoud A.M., Eissa M.H., et al. Hepatitis C virus infection at Sharkia Governorate Egypt: seroprevalence and associated risk factors. J Egypt Soc Parasitol 2004, 34:367-384.
20. Zainab D., Mezban M.D., Adil Ed Wakil M.D. Hepatitis C in Egypt. Am J Gastroenterol 2006.
21. Marcellin P., Levy S., Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997, 26:S133-S136.
22. Puoti C., Castellacci R., Montagnese F., Zaltron S., Stornaiuolo G., Bergami N., et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002, 37:117-123.
23. Puoti C., Guido M., Mangia A., Persico M., Prati D. Clinical management of HCV carriers with normal aminotransferases levels. Dig Liver Dis 2003, 35:362-369.
24. Persico M., Persico E., Suozzo R., Conte S., De Seta M., Coppola L., et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000, 118:760-764.
25. Calvaruso V., Craxi A. Implication of normal liver enzymes in liver disease. J Viral Hepat 2009, 16(8):529-536.
26. Shindo M., Arai K., Sokawa Y., Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995, 22:418-425.
27. Rumi M.G., De Filippi F., La Vecchia C., Donato M.F., Gallus S., Del Ninno E., et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005, 54(3):402-406.
28. Prieto M., Olaso V., Verdu C., Cordoba J., Gisbert C., Rayon M., et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995, 22:413-417.
29. Bacon B.R. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002, 36:S179-S184.
30. Pradat P., Alberti A., Poynard T., Esteban J.I., Weiland O., Marcellin P., et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002, 36(1):973-977.
31. Strader D.B., Wright T., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 9:1147.
32. Deuffic-Burban S., Babany G., Lonjon-Domanec I., Deltenre P., Canva-Delcambre V., Dharancy S., et al. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009, 50(5):1351-1359.
33. Zeuzem S., Diago M., Gane E., Reddy K.R., Pockros P., Prati D., et al. Peg interferon alpha 2-a(40 kilodalton) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004, 127:1724-1732.
34. Puoti C., Pellicelli A.M., Romano M., Mecenate F., Guarisco R., Barbarini G., et al. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peg interferon alpha 2-a and ribavirin: a multicentric study. Liver Int 2009, 29:1479-1484.